Tango Therapeutics (TNGX) Cash from Investing Activities (2020 - 2026)

Tango Therapeutics' Cash from Investing Activities history runs 7 years deep, the most recent figure standing at $9.6 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 68.51% year-over-year to $9.6 million; the TTM figure through Mar 2026 stood at -$61.8 million (down 148.33% YoY), while the FY2025 annual figure was -$40.9 million, down 147.45% from the prior year.
• Cash from Investing Activities was $9.6 million for Q1 2026 at Tango Therapeutics, up from -$135.7 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $52.1 million in Q4 2024 to a low of -$135.7 million in Q4 2025.
• Historically, Cash from Investing Activities has averaged $7.2 million across 5 years, with a median of $16.8 million in 2025.
• The sharpest annual moves came in 2022 and 2023: Cash from Investing Activities surged 635.74% in 2022, then sank 472.1% in 2023.
• A 5-year view of Cash from Investing Activities shows it stood at -$12.6 million in 2022, then soared by 368.56% to $33.9 million in 2023, then surged by 53.79% to $52.1 million in 2024, then tumbled by 360.69% to -$135.7 million in 2025, then soared by 107.1% to $9.6 million in 2026.
• The last three Cash from Investing Activities figures came in at $9.6 million (Q1 2026), -$135.7 million (Q4 2025), and $47.5 million (Q3 2025), per Business Quant data.